OBJECTIVE: Few studies have examined the dietary habits of ovarian cancer survivors. Therefore, we conducted a study to assess the feasibility and impact of two dietary interventions for ovarian cancer survivors. METHODS: In this randomized, parallel-group study, 51 women (mean age, 53 years) diagnosed with stages II-IV ovarian cancer were recruited and randomly assigned to a low fat, high fiber (LFHF) diet or a modified National Cancer Institute diet supplemented with a soy-based beverage and encapsulated fruit and vegetable juice concentrates (FVJCs). Changes in clinical measures, serum carotenoid and tocopherol levels, dietary intake, anthropometry, and health-related quality of life (HRQOL) were assessed with paired t-tests. RESULTS: The recruitment rate was 25%, and the retention rate was 75% at 6 months. At baseline, 28% and 45% of women met guidelines for intake of fiber and of fruits and vegetables, respectively. After 6 months, total serum carotenoid levels and α- and β-carotene concentrations were significantly increased in both groups (P<0.01); however, β-carotene concentrations were increased more in the FVJC group. Serum β-cryptoxanthin levels, fiber intake (+5.2g/day), and daily servings of juice (+0.9 servings/day) and vegetables (+1.3 servings/day) were all significantly increased in the LFHF group (all P<0.05). Serum levels of albumin, lutein and zeaxanthin, retinol, and retinyl palmitate were significantly increased in the FVJC group (all P<0.05). No changes in cancer antigen-125, anthropometry, or HRQOL were observed. CONCLUSION: Overall, this study supports the feasibility of designing dietary interventions for stages II-IV ovarian cancer survivors and provides preliminary evidence that a low fat high fiber diet and a diet supplemented with encapsulated FVJC may increase phytonutrients in ovarian cancer survivors.
RCT Entities:
OBJECTIVE: Few studies have examined the dietary habits of ovarian cancer survivors. Therefore, we conducted a study to assess the feasibility and impact of two dietary interventions for ovarian cancer survivors. METHODS: In this randomized, parallel-group study, 51 women (mean age, 53 years) diagnosed with stages II-IV ovarian cancer were recruited and randomly assigned to a low fat, high fiber (LFHF) diet or a modified National Cancer Institute diet supplemented with a soy-based beverage and encapsulated fruit and vegetable juice concentrates (FVJCs). Changes in clinical measures, serum carotenoid and tocopherol levels, dietary intake, anthropometry, and health-related quality of life (HRQOL) were assessed with paired t-tests. RESULTS: The recruitment rate was 25%, and the retention rate was 75% at 6 months. At baseline, 28% and 45% of women met guidelines for intake of fiber and of fruits and vegetables, respectively. After 6 months, total serum carotenoid levels and α- and β-carotene concentrations were significantly increased in both groups (P<0.01); however, β-carotene concentrations were increased more in the FVJC group. Serum β-cryptoxanthin levels, fiber intake (+5.2g/day), and daily servings of juice (+0.9 servings/day) and vegetables (+1.3 servings/day) were all significantly increased in the LFHF group (all P<0.05). Serum levels of albumin, lutein and zeaxanthin, retinol, and retinyl palmitate were significantly increased in the FVJC group (all P<0.05). No changes in cancer antigen-125, anthropometry, or HRQOL were observed. CONCLUSION: Overall, this study supports the feasibility of designing dietary interventions for stages II-IV ovarian cancer survivors and provides preliminary evidence that a low fat high fiber diet and a diet supplemented with encapsulated FVJC may increase phytonutrients in ovarian cancer survivors.
Authors: Christina M Nagle; David M Purdie; Penelope M Webb; Adèle Green; Philip W Harvey; Christopher J Bain Journal: Int J Cancer Date: 2003-08-20 Impact factor: 7.396
Authors: Ellen T Chang; Valerie S Lee; Alison J Canchola; Tapashi B Dalvi; Christina A Clarke; Peggy Reynolds; David M Purdie; Daniel O Stram; Dee W West; Argyrios Ziogas; Leslie Bernstein; Pamela L Horn-Ross Journal: Nutr Cancer Date: 2008 Impact factor: 2.900
Authors: J Brown Thomas; M C Kline; L M Gill; J H Yen; D L Duewer; L T Sniegoski; K E Sharpless Journal: Clin Chim Acta Date: 2001-03 Impact factor: 3.786
Authors: Keren Hirsch; Andrea Atzmon; Michael Danilenko; Joseph Levy; Yoav Sharoni Journal: Breast Cancer Res Treat Date: 2006-10-19 Impact factor: 4.872
Authors: John P Pierce; Loki Natarajan; Shelly Sun; Wael Al-Delaimy; Shirley W Flatt; Sheila Kealey; Cheryl L Rock; Cynthia A Thomson; Vicky A Newman; Cheryl Ritenbaugh; Ellen B Gold; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Colleen Doyle; Lawrence H Kushi; Tim Byers; Kerry S Courneya; Wendy Demark-Wahnefried; Barbara Grant; Anne McTiernan; Cheryl L Rock; Cyndi Thompson; Ted Gansler; Kimberly S Andrews Journal: CA Cancer J Clin Date: 2006 Nov-Dec Impact factor: 508.702
Authors: John P Pierce; Susan Faerber; Fred A Wright; Cheryl L Rock; Vicky Newman; Shirley W Flatt; Sheila Kealey; Vicky E Jones; Bette J Caan; Ellen B Gold; Mary Haan; Kathryn A Hollenbach; Lovell Jones; James R Marshall; Cheryl Ritenbaugh; Marcia L Stefanick; Cynthia Thomson; Linda Wasserman; Loki Natarajan; Ronald G Thomas; Elizabeth A Gilpin Journal: Control Clin Trials Date: 2002-12
Authors: Cynthia A Thomson; Tracy E Crane; Austin Miller; David O Garcia; Karen Basen-Engquist; David S Alberts Journal: Contemp Clin Trials Date: 2016-07-06 Impact factor: 2.226
Authors: Mridul Datta; Edward G Shaw; Glenn J Lesser; L Douglas Case; Mara Z Vitolins; Charles Schneider; Bart Frizzell; Christopher Sullivan; Mark Lively; Elizabeth Franzmann; Jennifer J Hu Journal: Integr Cancer Ther Date: 2017-01-19 Impact factor: 3.279
Authors: Sorrel Burden; Debra J Jones; Jana Sremanakova; Anne Marie Sowerbutts; Simon Lal; Mark Pilling; Chris Todd Journal: Cochrane Database Syst Rev Date: 2019-11-22